source
- Novo CEO accepts ‘couple of setbacks’ in R&D as CagriSema posts more mixed dataNovo Nordisk’s CEO admitted the Danish pharma has had “a couple of setbacks” in the wake of mixed data for CagriSema and its cardiovascular hopeful ziltivekimab, while stressing that the company is…Fierce Biotech · 12h ago↗ source
- Amgen halts development of early-stage obesity drug AMG 513, shifting focus to phase-3 candidate MariTideAmgen announced it is stopping work on AMG 513, an early-stage obesity therapy, during its second-quarter earnings call. The decision follows a previous FDA clinical hold in early 2025 that was la…
- KKR to acquire medtech maker Integer in $5.7 billion deal